295 related articles for article (PubMed ID: 35676794)
1. C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.
Maddaloni E; Bolli GB; Frier BM; Little RR; Leslie RD; Pozzilli P; Buzzetti R
Diabetes Obes Metab; 2022 Oct; 24(10):1912-1926. PubMed ID: 35676794
[TBL] [Abstract][Full Text] [Related]
2. The clinical utility of C-peptide measurement in the care of patients with diabetes.
Jones AG; Hattersley AT
Diabet Med; 2013 Jul; 30(7):803-17. PubMed ID: 23413806
[TBL] [Abstract][Full Text] [Related]
3. [The clinical utility of C-peptide measurement in diabetology].
Otto-Buczkowska E
Pediatr Endocrinol Diabetes Metab; 2015; 20(2):63-8. PubMed ID: 26615015
[TBL] [Abstract][Full Text] [Related]
4. Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes.
Saisho Y
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196896
[TBL] [Abstract][Full Text] [Related]
5. C-peptide and residual β-cell function in pediatric diabetes - state of the art.
Jamiołkowska-Sztabkowska M; Głowińska-Olszewska B; Bossowski A
Pediatr Endocrinol Diabetes Metab; 2021; 27(2):123-133. PubMed ID: 34514768
[TBL] [Abstract][Full Text] [Related]
6. Insulin Secretion Capacity as a Crucial Feature to Distinguish Type 1 From Type 2 Diabetes and to Indicate the Need for Insulin Therapy - A Critical Discussion of the ADA/EASD Consensus Statement on the Management of Type 1 Diabetes in Adults.
Fritsche A
Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):500-503. PubMed ID: 37308105
[TBL] [Abstract][Full Text] [Related]
7. Determination of C-peptide in children: when is it useful?
Besser RE
Pediatr Endocrinol Rev; 2013 Jul; 10(4):494-502. PubMed ID: 23957200
[TBL] [Abstract][Full Text] [Related]
8. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
[TBL] [Abstract][Full Text] [Related]
9. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9.
Hernandez M; Mollo A; Marsal JR; Esquerda A; Capel I; Puig-Domingo M; Pozzilli P; de Leiva A; Mauricio D;
BMC Endocr Disord; 2015 Jan; 15():1. PubMed ID: 25572256
[TBL] [Abstract][Full Text] [Related]
10. Rationale and methods for the estimation of insulin secretion in a given patient: from research to clinical practice.
Vague P; Nguyen L
Diabetes; 2002 Feb; 51 Suppl 1():S240-4. PubMed ID: 11815486
[TBL] [Abstract][Full Text] [Related]
11. [The natural history of diabetes with respect to disorders of insulin function].
Dorner M; Pinget M; Brogard JM; Sapin R; Paris-Bockel D; Levy P; Jung C
Journ Annu Diabetol Hotel Dieu; 1984; ():51-71. PubMed ID: 6399540
[No Abstract] [Full Text] [Related]
12. Harmonization of immunoassays for biomarkers in diabetes mellitus.
Hörber S; Achenbach P; Schleicher E; Peter A
Biotechnol Adv; 2020; 39():107359. PubMed ID: 30802485
[TBL] [Abstract][Full Text] [Related]
13. Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications.
Fritsche A; Heni M; Peter A; Gallwitz B; Kellerer M; Birkenfeld AL; Häring HU; Wagner R
Exp Clin Endocrinol Diabetes; 2022 Mar; 130(3):200-204. PubMed ID: 32947641
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.
Davis AK; DuBose SN; Haller MJ; Miller KM; DiMeglio LA; Bethin KE; Goland RS; Greenberg EM; Liljenquist DR; Ahmann AJ; Marcovina SM; Peters AL; Beck RW; Greenbaum CJ;
Diabetes Care; 2015 Mar; 38(3):476-81. PubMed ID: 25519448
[TBL] [Abstract][Full Text] [Related]
15. C-peptide used in the estimation of islet beta-cell function in diabetes.
Gjessing HJ
Dan Med Bull; 1992 Oct; 39(5):438-52. PubMed ID: 1424818
[No Abstract] [Full Text] [Related]
16. Insulin secretory capacity in Singapore diabetic subjects.
Thai AC; Yeo PP; Chan L; Wang KW; Lui KF; Cheah JS; Tan BY
Ann Acad Med Singap; 1985 Apr; 14(2):191-3. PubMed ID: 3898977
[TBL] [Abstract][Full Text] [Related]
17. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes.
Thomas NJ; Lynam AL; Hill AV; Weedon MN; Shields BM; Oram RA; McDonald TJ; Hattersley AT; Jones AG
Diabetologia; 2019 Jul; 62(7):1167-1172. PubMed ID: 30969375
[TBL] [Abstract][Full Text] [Related]
18. The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus.
Vlad A; Serban V; Sima A; Timar R; Roşu M
Rom J Intern Med; 2004; 42(2):333-41. PubMed ID: 15529624
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus.
Wakasaki H; Shono T; Nakao R; Yamamoto S; Minaga T; Fukuda S; Matsumoto R; Ohoshi T; Naka K; Nanjo K
Intern Med; 2020; 59(18):2229-2235. PubMed ID: 32938850
[TBL] [Abstract][Full Text] [Related]
20. Residual C-peptide in type 1 diabetes: what do we really know?
VanBuecken DE; Greenbaum CJ
Pediatr Diabetes; 2014 Mar; 15(2):84-90. PubMed ID: 24645775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
